Clinical trial
The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation
NCT00181142 · Johns Hopkins University, Other · Completed
Key facts
| NCT number | NCT00181142 |
|---|---|
| Title | The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation |
| Official title | A Phase 3 Study Comparing the Use of Daclizumab vs Thymoglobulin as Induction Therapy in Lung Transplantation |
| Lead sponsor | Johns Hopkins University, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Patients Active and Listed for Lung Transplantation |
| Intervention type | Drug |
| Interventions | Zenapax |
| Enrollment | 60 |
| Start date | Oct 1, 1999 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: